This correlation was enhanced in patients with conserved miR-let-7a-binding sequence in KRAS-coding mRNA, suggesting that patients with high tumor expression of miR-let-7a may benefit from an anti-EGFR therapy irrespective of KRAS mutational status [90]. The gene discussed is KRAS; the disease is neoplasm.